Human papillomavirus vaccination for adult women

Key points

• Update obstetrician–gynecologists about human papillomavirus (HPV) vaccination for adult women with Febrasgo position about this matter.

• Emphasize there is a generation of women who reached adulthood without HPV vaccination opportunity and highlight benefits provided by vaccine immunization.

• Address epidemiological and immunological aspects of HPV infection and available vaccines.

• Assess the susceptibility of unvaccinated adult women to oncogenic types of HPV and to lesions caused by HPV.

• Assess the difference in susceptibility to recurrence and reinfections after treatment of HPV-associated lesions among vaccinated adult women compared to unvaccinated adult women.

• Provide knowledge of best evidence for HPV vaccination among adult women and collaborate for an updated clinical practice.

The National Specialty Commission for Vaccines of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.

Publikationsverlauf

Artikel online veröffentlicht:
12. Juli 2022

• Referências

• 1 Drolet M, Bénard E, Pérez N, Brisson M. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394 (10197): 497-509
• 2 Saslow D, Andrews KS, Manassaram-Baptiste D, Smith RA, Fontham ETH. American Cancer Society Guideline Development Group. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin 2020; 70 (04) 274-80
• 3 Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunização e Doenças Transmissíveis. Coordenação Geral do Programa Nacional de Imunizações. [Official Letter No 203/2021/CGPNI/DEIDT/SVS/MS. Expansion of the age range of the HPV vaccine for women with immunosuppression up to 45 years] [Internet]. 2021 [cited 2022 Jan 10]. Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf. Portuguese.
• 4 ICO/IARC Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary Report 2019 [Internet]. 2019 [cited 2019 Jul 3]. Available from: https://www.hpvcentre.net/statistics/reports/XWX.pdf
• 5 Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 2012; 18 (06) 807-15
• 6 Muñoz N, Méndez F, Posso H, Molano M, van den Brule AJ, Ronderos M. et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190 (12) 2077-87
• 7 Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC. et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191 (11) 1808-16
• 8 Ministério da Saúde. Instituto Nacional de Câncer. Controle do câncer do colo do útero: conceito e magnitude [Internet]. Rio de Janeiro: INCA; 2020 [cited 2020 Nov 11]. Available from: https://www.inca.gov.br/controle-do-cancer-do-colo-do-utero/conceito-e-magnitude
• 9 de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11) 1048-56
• 10 Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC. et al. Seroreactivity to Human Papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13 (02) 324-7
• 11 Wiley DJ, Masongsong EV, Lu S, Heather LS, Salem B, Giuliano AR. et al. Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV 6,11,16,18 infections. Cancer Epidemiol 2012; 36 (03) e183-9
• 12 Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K. et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105 (01) 28-37
• 13 Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN 2-3)?. Gynecol Oncol 2013; 130 (02) 264-8
• 14 Velentzis LS, Brotherton JML, Canfell K. Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric 2019; 22 (06) 596-602
• 15 Jentschke M, Kampers J, Hillemanns P. HPV vaccination after conization: a systematic review and meta-analysis [Internet]. 2021 [cited 2022 Apr 7]. Available from: https://www.hpvworld.com/articles/hpv-vaccination-after-conization/
• 16 Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 2009; 36 (11) 696-703
• 17 Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F. et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383 (14) 1340-8
• 18 International Federation of Gynecology & Obstetrics. Global guidance for cervical cancer prevention and control [Internet]. London: FIGO; 2009. [cited 2017 Jul 4]. Available from: https://screening.iarc.fr/doc/FIGO-Global-Guidance-for-Cervical-Cancer-Prevention-and-Control_1.pdf
• 19 Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E. et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis 2016; 16 (10) 1154-68
• 20 Kim JJ. Effect of quadrivalent HPV vaccination on HPV related disease in women treated for cervical or vulvar/vaginal disease. BMJ 2012; 344: e1544
• 21 Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S. et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of health women aged 18-45 anos. Hum Vaccin 2011; 7 (12) 1343-58
• 22 Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C. et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS One 2013; 8 (12) e83431
• 23 Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018; 5 (05) CD009069